HTG Molecular Diagnostics with ticker code (HTGM) have now 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 1.5 and 0.4 with a mean TP of 0.98. Now with the previous closing price of 0.29 this indicates there is a potential upside of 237.9%. The 50 day MA is 0.31 and the 200 moving average now moves to 0.47. The company has a market capitalisation of $1m. Visit the company website at: http://www.htgmolecular.com
HTG Molecular Diagnostics a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company’s marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG and changed its name to HTG Molecular Diagnostics in March 2011. HTG Molecular Diagnostics was incorporated in 1997 and is based in Tucson, Arizona.